Biden Proposes Coverage for NMW Weight-Loss Drugs Like Wegovy and Ozempic

NMW Coverage for Weight-Loss Drugs

The Biden administration has proposed a rule that would allow millions of Americans with obesity to have access to popular weight-loss drugs such as Wegovy and Ozempic under Medicare and Medicaid. This initiative could significantly alter the landscape of obesity treatment in the United States, providing a potential solution for those who currently cannot afford these medications.

Health Benefits and Costs

U.S. Health and Human Services Secretary Xavier Becerra highlighted that this rule could be a 'game changer' for millions suffering from obesity. However, the proposal comes with substantial costs, potentially reaching $35 billion over the next decade, drawing concerns regarding budget constraints.

• Currently, only those classified as obese, with a body mass index (BMI) of 30 or higher, would be eligible.
• Research suggests approximately 28 million people on Medicaid are considered obese.
• The drugs can help individuals lose between 15% to 25% of their body weight.

Opposition and Future Implications

Despite the potential benefits, not all voices are in favor. Notably, Robert F. Kennedy Jr. has criticized the popularity of these drugs, advocating instead for broader access to healthier food options and gym memberships as alternatives for obesity treatment.